Myriad has indicated the launch of 2 new molecular diagnostic products in 2010, so the next one will probably be a pancreatic cancer test (they have mentioned a pancreatic cancer gene they will probably combine with BRCA2 and P16).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.